XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > $2 by end of December

<< Previous

Bullboard Posts

Next >>

Post by Richmondon Nov 12, 2021 4:45pm

222 Views

Post# 34121669

$2 by end of December

And than back to pre-rollback share price of .35c. The Scammer Management have taken the investors( shareholders on a wild ride. The proof is in front of you. Share Price tumbling daily!!! From $9.00 to $3.00.. DYOR!!! or DYODD... BAGHOLDERS ARE ROYALLY FCUKED!!!!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing